Recombinant immunotoxins.
Pseudomonas exotoxin has been genetically modified so that it targets cancer cells. This was accomplished by deleting its cell binding domain and replacing it with Fv fragments of antibodies that react with breast, colon, and other cancers. Several recombinant immunotoxins are now in clinical trials.
Pastan
I
I
Laboratory of Molecular Biology, DCBDC, National Cancer Institute, NIH, Bethesda, MD, USA.
Pai
L H
LH
Brinkmann
U
U
FitzGerald
D
D
D036002:ADP Ribose Transferases; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001427:Bacterial Toxins; D001943:Breast Neoplasms / Q000628:therapy*; D005098:Exotoxins / Q000627:therapeutic use; D005260:Female; D006801:Humans; D000922:Immunotoxins / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A
D036002:ADP Ribose Transferases; D000911:Antibodies, Monoclonal; D001427:Bacterial Toxins; D005098:Exotoxins; D000922:Immunotoxins; D011994:Recombinant Proteins; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A